Erratum: miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer (Int J Oncol (2015) 48 (181-190) DOI: 10.3892/ijo.2015.3241);MiR 382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer

International Journal of Oncology

Volumn 48, Issue 1, 2016, Pages 181-190

  Tan, Hong ^a,b   He, Qingnan ^c   Gong, Guanhui ^b   Wang, Yixuan ^a,b   Li, Juanni ^a,b   Wang, Junpu ^a,b   Zhu, Ding ^a,b   Wu, Xiaoying ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Epithelial mesenchymal transition; Invasion; Migration; MiR 382; Ovarian cancer; Receptor tyrosine kinase orphan receptor 1

Indexed keywords

BETA ACTIN; MICRORNA; MICRORNA 382; NERVE CELL ADHESION MOLECULE; PROTEIN TYROSINE KINASE; RECEPTOR TYROSINE KINASE ORPHAN RECEPTOR 1; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; MIRN382 MICRORNA, HUMAN; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; ROR1 PROTEIN, HUMAN;

ARTICLE; BIOLOGICAL FUNCTIONS; CANCER TISSUE; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MIGRATION INHIBITION; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR INVASION; BIOSYNTHESIS; CARCINOGENESIS; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; OVARY TUMOR; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

CARCINOGENESIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS;

EID: 84953268701     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2024.5698     Document Type: Erratum

References (29)

1. Macha MA, Seshacharyulu P, Krishn SR, Pai P, Rachagani S, Jain M and Batra SK: MicroRNAs (miRNAs) as biomarker(s) for prognosis and diagnosis of gastrointestinal (GI) cancers. Curr Pharm Des 20: 5287-5297, 2014.
2. Ebert MS and Sharp PA: Roles for microRNAs in conferring robustness to biological processes. Cell 149: 515-524, 2012.
3. Ruepp A, Kowarsch A and Theis F: PhenomiR: microRNAs in human diseases and biological processes. Methods Mol Biol 822: 249-260, 2012.
4. Tüfekci KU, Meuwissen RL and Genç S: The role of microRNAs in biological processes. Methods Mol Biol 1107: 15-31, 2014.
5. Tricoli JV and Jacobson JW: MicroRNA: Potential for cancer detection, diagnosis, and prognosis. Cancer Res 67: 4553-4555, 2007.
6. Dahiya N and Morin PJ: MicroRNAs in ovarian carcinomas. Endocr Relat Cancer 17: F77-F89, 2010.
7. Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O'Briant K, Godwin AK, Urban N, Drescher CW, Knudsen BS and Tewari M: Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One 4: e5311, 2009.
8. Thériault BL, Basavarajappa HD, Lim H, Pajovic S, Gallie BL and Corson TW: Transcriptional and epigenetic regulation of KIF14 overexpression in ovarian cancer. PLoS One 9: e91540, 2014.
9. Gschwind A, Fischer OM and Ullrich A: The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat Rev Cancer 4: 361-370, 2004.
10. Zhang S, Cui B, Lai H, Liu G, Ghia EM, Widhopf GF II, Zhang Z, Wu CC, Chen L, Wu R, et al: Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci USA 111: 17266-17271, 2014.
11. Zhang H, Qiu J, Ye C, Yang D, Gao L, Su Y, Tang X, Xu N, Zhang D, Xiong L, et al: ROR1 expression correlated with poor clinical outcome in human ovarian cancer. Sci Rep 4: 5811, 2014.
12. Böcker W: WHO classification of breast tumors and tumors of the female genital organs: Pathology and genetics. Verh Dtsch Ges Pathol 86: 116-119, 2002 (In German).
13. Kan CW, Howell VM, Hahn MA and Marsh DJ: Genomic alterations as mediators of miRNA dysregulation in ovarian cancer. Genes Chromosomes Cancer 54: 1-19, 2015.
14. Vargas-Hernández VM, Moreno-Eutimio MA, Acosta-Altamirano G and Vargas-Aguilar VM: Management of recurrent epithelial ovarian cancer. Gland Surg 3: 198-202, 2014.
15. Goff BA, Mandel L, Muntz HG and Melancon CH: Ovarian carcinoma diagnosis. Cancer 89: 2068-2075, 2000.
16. Zhou XM, Zhang H and Han X: Role of epithelial to mesenchymal transition proteins in gynecological cancers: Pathological and therapeutic perspectives. Tumour Biol 35: 9523-9530, 2014.
17. Wang DH, Guo L and Wu XH: Checkpoint inhibitors in immunotherapy of ovarian cancer. Tumour Biol 36: 33-39, 2015.
18. Muccioli M and Benencia F: Toll-like Receptors in ovarian cancer as targets for immunotherapies. Front Immunol 5: 341, 2014.
19. Garces AH, Dias MS, Paulino E, Ferreira CG and de Melo AC: Treatment of ovarian cancer beyond chemotherapy: Are we hitting the target? Cancer Chemother Pharmacol 75: 221-234, 2015.
20. Sethi S, Ali S, Sethi S and Sarkar FH: MicroRNAs in personalized cancer therapy. Clin Genet 86: 68-73, 2014.
21. Casanova-Salas I, Rubio-Briones J, Calatrava A, Mancarella C, Masiá E, Casanova J, Fernández-Serra A, Rubio L, Ramírez-Backhaus M, Armiñán A, et al: Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy. J Urol 192: 252-259, 2014.
22. Jiang C, Chen X, Alattar M, Wei J and Liu H: MicroRNAs in tumorigenesis, metastasis, diagnosis and prognosis of gastric cancer. Cancer Gene Ther 22: 291-301, 2015.
23. Li SQ, Chen FJ and Cao XF: Distinctive microRNAs in esophageal tumor: Early diagnosis, prognosis judgment, and tumor treatment. Dis Esophagus 26: 288-298, 2013.
24. Gounaris-Shannon S and Chevassut T: The role of miRNA in haematological malignancy. Bone Marrow Res 2013: 269107, 2013.
25. Sethi S, Kong D, Land S, Dyson G, Sakr WA and Sarkar FH: Comprehensive molecular oncogenomic profiling and miRNA analysis of prostate cancer. Am J Transl Res 5: 200-211, 2013.
26. Koutsaki M, Spandidos DA and Zaravinos A: Epithelialmesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: Prognostic value and prospective role in ovarian cancer therapeutics. Cancer Lett 351: 173-181, 2014.
27. Takai M, Terai Y, Kawaguchi H, Ashihara K, Fujiwara S, Tanaka T, Tsunetoh S, Tanaka Y, Sasaki H, Kanemura M, et al: The EMT (epithelial-mesenchymal-transition)-related protein expression indicates the metastatic status and prognosis in patients with ovarian cancer. J Ovarian Res 7: 76, 2014.
28. Xu M, Jin H, Xu CX, Sun B, Song ZG, Bi WZ and Wang Y: miR 382 inhibits osteosarcoma metastasis and relapse by targeting Y box-binding protein 1. Mol Ther 23: 89-98, 2015.
29. Cui B, Zhang S, Chen L, Yu J, Widhopf GF II, Fecteau JF, Rassenti LZ and Kipps TJ: Targeting ROR1 inhibits epithelialmesenchymal transition and metastasis. Cancer Res 73: 3649-3660, 2013.